nodes	percent_of_prediction	percent_of_DWPC	metapath
Zileuton—UGT1A9—Mycophenolic acid—psoriasis	0.267	0.34	CbGbCtD
Zileuton—UGT1A9—Mycophenolate mofetil—psoriasis	0.149	0.19	CbGbCtD
Zileuton—CYP1A2—Clobetasol propionate—psoriasis	0.0919	0.117	CbGbCtD
Zileuton—CYP1A2—Methoxsalen—psoriasis	0.0483	0.0613	CbGbCtD
Zileuton—CYP3A4—Calcitriol—psoriasis	0.0325	0.0413	CbGbCtD
Zileuton—CYP2C9—Cholecalciferol—psoriasis	0.0288	0.0366	CbGbCtD
Zileuton—CYP3A4—Methoxsalen—psoriasis	0.0253	0.0321	CbGbCtD
Zileuton—CYP2C9—Cyclosporine—psoriasis	0.0189	0.024	CbGbCtD
Zileuton—CYP3A4—Cholecalciferol—psoriasis	0.0168	0.0213	CbGbCtD
Zileuton—CYP3A4—Mycophenolate mofetil—psoriasis	0.0145	0.0185	CbGbCtD
Zileuton—CYP3A4—Triamcinolone—psoriasis	0.0145	0.0185	CbGbCtD
Zileuton—CYP2C9—Dexamethasone—psoriasis	0.0125	0.0158	CbGbCtD
Zileuton—CYP3A4—Betamethasone—psoriasis	0.0125	0.0158	CbGbCtD
Zileuton—CYP3A4—Prednisolone—psoriasis	0.0123	0.0156	CbGbCtD
Zileuton—CYP3A4—Hydrocortisone—psoriasis	0.0117	0.0148	CbGbCtD
Zileuton—CYP3A4—Prednisone—psoriasis	0.0116	0.0148	CbGbCtD
Zileuton—CYP3A4—Cyclosporine—psoriasis	0.011	0.014	CbGbCtD
Zileuton—CYP3A4—Dexamethasone—psoriasis	0.00725	0.00921	CbGbCtD
Zileuton—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00115	0.0521	CbGpPWpGaD
Zileuton—EPHX2—Metapathway biotransformation—CYP2S1—psoriasis	0.000991	0.0449	CbGpPWpGaD
Zileuton—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000712	0.0323	CbGpPWpGaD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000688	0.0312	CbGpPWpGaD
Zileuton—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000609	0.0276	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—HCAR2—psoriasis	0.000524	0.0237	CbGpPWpGaD
Zileuton—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00047	0.0213	CbGpPWpGaD
Zileuton—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000456	0.0207	CbGpPWpGaD
Zileuton—Dyspepsia—Hydroxyurea—psoriasis	0.000422	0.00221	CcSEcCtD
Zileuton—Chest pain—Mycophenolic acid—psoriasis	0.000419	0.0022	CcSEcCtD
Zileuton—Myalgia—Mycophenolic acid—psoriasis	0.000419	0.0022	CcSEcCtD
Zileuton—Arthralgia—Mycophenolic acid—psoriasis	0.000419	0.0022	CcSEcCtD
Zileuton—Diarrhoea—Acitretin—psoriasis	0.000418	0.00219	CcSEcCtD
Zileuton—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000417	0.00218	CcSEcCtD
Zileuton—Conjunctivitis—Triamcinolone—psoriasis	0.000414	0.00217	CcSEcCtD
Zileuton—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000414	0.00217	CcSEcCtD
Zileuton—Discomfort—Mycophenolic acid—psoriasis	0.000414	0.00217	CcSEcCtD
Zileuton—Constipation—Hydroxyurea—psoriasis	0.00041	0.00215	CcSEcCtD
Zileuton—Pain—Hydroxyurea—psoriasis	0.00041	0.00215	CcSEcCtD
Zileuton—Nausea—Calcitriol—psoriasis	0.000408	0.00214	CcSEcCtD
Zileuton—Dizziness—Acitretin—psoriasis	0.000404	0.00212	CcSEcCtD
Zileuton—Dizziness—Fluocinolone Acetonide—psoriasis	0.000403	0.00211	CcSEcCtD
Zileuton—Feeling abnormal—Hydroxyurea—psoriasis	0.000395	0.00207	CcSEcCtD
Zileuton—Flatulence—Cyclosporine—psoriasis	0.000392	0.00206	CcSEcCtD
Zileuton—Tension—Cyclosporine—psoriasis	0.000391	0.00205	CcSEcCtD
Zileuton—Vomiting—Acitretin—psoriasis	0.000388	0.00203	CcSEcCtD
Zileuton—Vomiting—Fluocinolone Acetonide—psoriasis	0.000387	0.00203	CcSEcCtD
Zileuton—Nervousness—Cyclosporine—psoriasis	0.000387	0.00203	CcSEcCtD
Zileuton—Rash—Acitretin—psoriasis	0.000385	0.00202	CcSEcCtD
Zileuton—Dermatitis—Acitretin—psoriasis	0.000385	0.00202	CcSEcCtD
Zileuton—Rash—Fluocinolone Acetonide—psoriasis	0.000384	0.00201	CcSEcCtD
Zileuton—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000384	0.00201	CcSEcCtD
Zileuton—Flatulence—Mycophenolate mofetil—psoriasis	0.000383	0.00201	CcSEcCtD
Zileuton—Headache—Acitretin—psoriasis	0.000383	0.002	CcSEcCtD
Zileuton—Headache—Fluocinolone Acetonide—psoriasis	0.000381	0.002	CcSEcCtD
Zileuton—Tension—Mycophenolate mofetil—psoriasis	0.000381	0.002	CcSEcCtD
Zileuton—Body temperature increased—Hydroxyurea—psoriasis	0.000379	0.00199	CcSEcCtD
Zileuton—Nervousness—Mycophenolate mofetil—psoriasis	0.000377	0.00198	CcSEcCtD
Zileuton—Conjunctivitis—Betamethasone—psoriasis	0.000376	0.00197	CcSEcCtD
Zileuton—Conjunctivitis—Dexamethasone—psoriasis	0.000376	0.00197	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—IL4—psoriasis	0.000375	0.017	CbGpPWpGaD
Zileuton—Ill-defined disorder—Cyclosporine—psoriasis	0.000369	0.00194	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000366	0.00192	CcSEcCtD
Zileuton—Insomnia—Mycophenolic acid—psoriasis	0.000363	0.0019	CcSEcCtD
Zileuton—Nausea—Acitretin—psoriasis	0.000363	0.0019	CcSEcCtD
Zileuton—Nausea—Fluocinolone Acetonide—psoriasis	0.000362	0.0019	CcSEcCtD
Zileuton—Ill-defined disorder—Mycophenolate mofetil—psoriasis	0.00036	0.00189	CcSEcCtD
Zileuton—Malaise—Cyclosporine—psoriasis	0.000359	0.00188	CcSEcCtD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000357	0.0162	CbGpPWpGaD
Zileuton—Somnolence—Mycophenolic acid—psoriasis	0.000357	0.00187	CcSEcCtD
Zileuton—Dyspepsia—Mycophenolic acid—psoriasis	0.000353	0.00185	CcSEcCtD
Zileuton—Hypersensitivity—Hydroxyurea—psoriasis	0.000353	0.00185	CcSEcCtD
Zileuton—Malaise—Mycophenolate mofetil—psoriasis	0.00035	0.00183	CcSEcCtD
Zileuton—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000347	0.00182	CcSEcCtD
Zileuton—Constipation—Mycophenolic acid—psoriasis	0.000343	0.0018	CcSEcCtD
Zileuton—Pain—Mycophenolic acid—psoriasis	0.000343	0.0018	CcSEcCtD
Zileuton—Myalgia—Cyclosporine—psoriasis	0.000339	0.00178	CcSEcCtD
Zileuton—Chest pain—Cyclosporine—psoriasis	0.000339	0.00178	CcSEcCtD
Zileuton—Arthralgia—Cyclosporine—psoriasis	0.000339	0.00178	CcSEcCtD
Zileuton—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000337	0.0153	CbGpPWpGaD
Zileuton—Ill-defined disorder—Prednisolone—psoriasis	0.000336	0.00176	CcSEcCtD
Zileuton—Discomfort—Cyclosporine—psoriasis	0.000335	0.00175	CcSEcCtD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000331	0.015	CbGpPWpGaD
Zileuton—Feeling abnormal—Mycophenolic acid—psoriasis	0.000331	0.00173	CcSEcCtD
Zileuton—Chest pain—Mycophenolate mofetil—psoriasis	0.000331	0.00173	CcSEcCtD
Zileuton—Arthralgia—Mycophenolate mofetil—psoriasis	0.000331	0.00173	CcSEcCtD
Zileuton—Myalgia—Mycophenolate mofetil—psoriasis	0.000331	0.00173	CcSEcCtD
Zileuton—Ill-defined disorder—Hydrocortisone—psoriasis	0.000328	0.00172	CcSEcCtD
Zileuton—Diarrhoea—Hydroxyurea—psoriasis	0.000328	0.00172	CcSEcCtD
Zileuton—Malaise—Prednisolone—psoriasis	0.000327	0.00171	CcSEcCtD
Zileuton—Discomfort—Mycophenolate mofetil—psoriasis	0.000327	0.00171	CcSEcCtD
Zileuton—Malaise—Hydrocortisone—psoriasis	0.000319	0.00167	CcSEcCtD
Zileuton—Body temperature increased—Mycophenolic acid—psoriasis	0.000317	0.00166	CcSEcCtD
Zileuton—Dizziness—Hydroxyurea—psoriasis	0.000317	0.00166	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—LEP—psoriasis	0.000317	0.0144	CbGpPWpGaD
Zileuton—Ill-defined disorder—Triamcinolone—psoriasis	0.000309	0.00162	CcSEcCtD
Zileuton—Vomiting—Hydroxyurea—psoriasis	0.000305	0.0016	CcSEcCtD
Zileuton—Discomfort—Prednisolone—psoriasis	0.000305	0.0016	CcSEcCtD
Zileuton—Rash—Hydroxyurea—psoriasis	0.000302	0.00158	CcSEcCtD
Zileuton—Dermatitis—Hydroxyurea—psoriasis	0.000302	0.00158	CcSEcCtD
Zileuton—Myalgia—Hydrocortisone—psoriasis	0.000301	0.00158	CcSEcCtD
Zileuton—Malaise—Triamcinolone—psoriasis	0.0003	0.00157	CcSEcCtD
Zileuton—Headache—Hydroxyurea—psoriasis	0.0003	0.00157	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—ICAM1—psoriasis	0.000298	0.0135	CbGpPWpGaD
Zileuton—Discomfort—Hydrocortisone—psoriasis	0.000298	0.00156	CcSEcCtD
Zileuton—UGT1A9—Biological oxidations—CYP2S1—psoriasis	0.000297	0.0135	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—HCAR2—psoriasis	0.000296	0.0134	CbGpPWpGaD
Zileuton—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000296	0.00155	CcSEcCtD
Zileuton—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000296	0.0134	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—NOS2—psoriasis	0.000295	0.0134	CbGpPWpGaD
Zileuton—Insomnia—Cyclosporine—psoriasis	0.000294	0.00154	CcSEcCtD
Zileuton—Upper respiratory tract infection—Methotrexate—psoriasis	0.000293	0.00154	CcSEcCtD
Zileuton—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000293	0.0133	CbGpPWpGaD
Zileuton—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000292	0.0132	CbGpPWpGaD
Zileuton—Somnolence—Cyclosporine—psoriasis	0.000289	0.00151	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000289	0.00151	CcSEcCtD
Zileuton—ALOX5—Selenium Micronutrient Network—CAT—psoriasis	0.000287	0.013	CbGpPWpGaD
Zileuton—Insomnia—Mycophenolate mofetil—psoriasis	0.000287	0.0015	CcSEcCtD
Zileuton—Dyspepsia—Cyclosporine—psoriasis	0.000286	0.0015	CcSEcCtD
Zileuton—Nausea—Hydroxyurea—psoriasis	0.000285	0.00149	CcSEcCtD
Zileuton—Pruritus—Mycophenolic acid—psoriasis	0.000284	0.00149	CcSEcCtD
Zileuton—Myalgia—Triamcinolone—psoriasis	0.000284	0.00149	CcSEcCtD
Zileuton—Somnolence—Mycophenolate mofetil—psoriasis	0.000282	0.00148	CcSEcCtD
Zileuton—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00028	0.00147	CcSEcCtD
Zileuton—Ill-defined disorder—Dexamethasone—psoriasis	0.00028	0.00147	CcSEcCtD
Zileuton—Ill-defined disorder—Betamethasone—psoriasis	0.00028	0.00147	CcSEcCtD
Zileuton—Discomfort—Triamcinolone—psoriasis	0.00028	0.00147	CcSEcCtD
Zileuton—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000279	0.00146	CcSEcCtD
Zileuton—Constipation—Cyclosporine—psoriasis	0.000278	0.00146	CcSEcCtD
Zileuton—Pain—Cyclosporine—psoriasis	0.000278	0.00146	CcSEcCtD
Zileuton—Diarrhoea—Mycophenolic acid—psoriasis	0.000275	0.00144	CcSEcCtD
Zileuton—Conjunctivitis—Methotrexate—psoriasis	0.000274	0.00143	CcSEcCtD
Zileuton—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000274	0.00143	CcSEcCtD
Zileuton—Malaise—Betamethasone—psoriasis	0.000273	0.00143	CcSEcCtD
Zileuton—Malaise—Dexamethasone—psoriasis	0.000273	0.00143	CcSEcCtD
Zileuton—LTB4R—GPCR ligand binding—CCL20—psoriasis	0.000272	0.0123	CbGpPWpGaD
Zileuton—Pain—Mycophenolate mofetil—psoriasis	0.000271	0.00142	CcSEcCtD
Zileuton—Constipation—Mycophenolate mofetil—psoriasis	0.000271	0.00142	CcSEcCtD
Zileuton—LTB4R—Signaling by GPCR—HCAR2—psoriasis	0.000269	0.0122	CbGpPWpGaD
Zileuton—Feeling abnormal—Cyclosporine—psoriasis	0.000268	0.0014	CcSEcCtD
Zileuton—Insomnia—Prednisolone—psoriasis	0.000267	0.0014	CcSEcCtD
Zileuton—Dizziness—Mycophenolic acid—psoriasis	0.000266	0.00139	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000263	0.00138	CcSEcCtD
Zileuton—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000261	0.00137	CcSEcCtD
Zileuton—Insomnia—Hydrocortisone—psoriasis	0.000261	0.00137	CcSEcCtD
Zileuton—Urticaria—Cyclosporine—psoriasis	0.000258	0.00135	CcSEcCtD
Zileuton—Myalgia—Betamethasone—psoriasis	0.000257	0.00135	CcSEcCtD
Zileuton—Myalgia—Dexamethasone—psoriasis	0.000257	0.00135	CcSEcCtD
Zileuton—Body temperature increased—Cyclosporine—psoriasis	0.000257	0.00135	CcSEcCtD
Zileuton—Vomiting—Mycophenolic acid—psoriasis	0.000255	0.00134	CcSEcCtD
Zileuton—Discomfort—Betamethasone—psoriasis	0.000254	0.00133	CcSEcCtD
Zileuton—Discomfort—Dexamethasone—psoriasis	0.000254	0.00133	CcSEcCtD
Zileuton—Dyspepsia—Hydrocortisone—psoriasis	0.000254	0.00133	CcSEcCtD
Zileuton—Rash—Mycophenolic acid—psoriasis	0.000253	0.00133	CcSEcCtD
Zileuton—Dermatitis—Mycophenolic acid—psoriasis	0.000253	0.00133	CcSEcCtD
Zileuton—Pain—Prednisolone—psoriasis	0.000253	0.00132	CcSEcCtD
Zileuton—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000253	0.0115	CbGpPWpGaD
Zileuton—Hepatitis—Methotrexate—psoriasis	0.000253	0.00132	CcSEcCtD
Zileuton—Urticaria—Mycophenolate mofetil—psoriasis	0.000252	0.00132	CcSEcCtD
Zileuton—Headache—Mycophenolic acid—psoriasis	0.000252	0.00132	CcSEcCtD
Zileuton—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000251	0.00131	CcSEcCtD
Zileuton—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000249	0.0113	CbGpPWpGaD
Zileuton—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000249	0.00131	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000248	0.0013	CcSEcCtD
Zileuton—Pain—Hydrocortisone—psoriasis	0.000247	0.00129	CcSEcCtD
Zileuton—Insomnia—Triamcinolone—psoriasis	0.000246	0.00129	CcSEcCtD
Zileuton—Ill-defined disorder—Prednisone—psoriasis	0.000244	0.00128	CcSEcCtD
Zileuton—Feeling abnormal—Prednisolone—psoriasis	0.000244	0.00128	CcSEcCtD
Zileuton—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000242	0.011	CbGpPWpGaD
Zileuton—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00024	0.0109	CbGpPWpGaD
Zileuton—Hypersensitivity—Cyclosporine—psoriasis	0.000239	0.00125	CcSEcCtD
Zileuton—Dyspepsia—Triamcinolone—psoriasis	0.000239	0.00125	CcSEcCtD
Zileuton—Nausea—Mycophenolic acid—psoriasis	0.000239	0.00125	CcSEcCtD
Zileuton—Feeling abnormal—Hydrocortisone—psoriasis	0.000238	0.00125	CcSEcCtD
Zileuton—Malaise—Prednisone—psoriasis	0.000237	0.00124	CcSEcCtD
Zileuton—Urticaria—Prednisolone—psoriasis	0.000235	0.00123	CcSEcCtD
Zileuton—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000233	0.00122	CcSEcCtD
Zileuton—Pain—Triamcinolone—psoriasis	0.000232	0.00122	CcSEcCtD
Zileuton—Pruritus—Cyclosporine—psoriasis	0.00023	0.0012	CcSEcCtD
Zileuton—Urticaria—Hydrocortisone—psoriasis	0.000229	0.0012	CcSEcCtD
Zileuton—Body temperature increased—Hydrocortisone—psoriasis	0.000228	0.0012	CcSEcCtD
Zileuton—ALOX5—Selenium Micronutrient Network—CRP—psoriasis	0.000228	0.0103	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—IFNG—psoriasis	0.000226	0.0103	CbGpPWpGaD
Zileuton—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000225	0.00118	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000225	0.00118	CcSEcCtD
Zileuton—Pruritus—Mycophenolate mofetil—psoriasis	0.000224	0.00117	CcSEcCtD
Zileuton—Arthralgia—Prednisone—psoriasis	0.000224	0.00117	CcSEcCtD
Zileuton—Myalgia—Prednisone—psoriasis	0.000224	0.00117	CcSEcCtD
Zileuton—Feeling abnormal—Triamcinolone—psoriasis	0.000224	0.00117	CcSEcCtD
Zileuton—Insomnia—Betamethasone—psoriasis	0.000223	0.00117	CcSEcCtD
Zileuton—Insomnia—Dexamethasone—psoriasis	0.000223	0.00117	CcSEcCtD
Zileuton—Diarrhoea—Cyclosporine—psoriasis	0.000222	0.00116	CcSEcCtD
Zileuton—Discomfort—Prednisone—psoriasis	0.000221	0.00116	CcSEcCtD
Zileuton—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000219	0.00992	CbGpPWpGaD
Zileuton—Hypersensitivity—Prednisolone—psoriasis	0.000218	0.00114	CcSEcCtD
Zileuton—Dyspepsia—Dexamethasone—psoriasis	0.000217	0.00114	CcSEcCtD
Zileuton—Dyspepsia—Betamethasone—psoriasis	0.000217	0.00114	CcSEcCtD
Zileuton—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000217	0.00114	CcSEcCtD
Zileuton—Urticaria—Triamcinolone—psoriasis	0.000216	0.00113	CcSEcCtD
Zileuton—Body temperature increased—Triamcinolone—psoriasis	0.000215	0.00113	CcSEcCtD
Zileuton—Dizziness—Cyclosporine—psoriasis	0.000215	0.00113	CcSEcCtD
Zileuton—Gastrointestinal disorder—Betamethasone—psoriasis	0.000213	0.00112	CcSEcCtD
Zileuton—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000213	0.00112	CcSEcCtD
Zileuton—Hypersensitivity—Hydrocortisone—psoriasis	0.000213	0.00111	CcSEcCtD
Zileuton—Pain—Betamethasone—psoriasis	0.000211	0.00111	CcSEcCtD
Zileuton—Pain—Dexamethasone—psoriasis	0.000211	0.00111	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—CXCL8—psoriasis	0.000211	0.00955	CbGpPWpGaD
Zileuton—Dizziness—Mycophenolate mofetil—psoriasis	0.00021	0.0011	CcSEcCtD
Zileuton—ALOX5—Selenium Micronutrient Network—ICAM1—psoriasis	0.000209	0.00949	CbGpPWpGaD
Zileuton—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	0.000208	0.00941	CbGpPWpGaD
Zileuton—Vomiting—Cyclosporine—psoriasis	0.000207	0.00108	CcSEcCtD
Zileuton—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000205	0.00929	CbGpPWpGaD
Zileuton—Rash—Cyclosporine—psoriasis	0.000205	0.00107	CcSEcCtD
Zileuton—Dermatitis—Cyclosporine—psoriasis	0.000205	0.00107	CcSEcCtD
Zileuton—Pruritus—Hydrocortisone—psoriasis	0.000204	0.00107	CcSEcCtD
Zileuton—Ill-defined disorder—Methotrexate—psoriasis	0.000204	0.00107	CcSEcCtD
Zileuton—Headache—Cyclosporine—psoriasis	0.000204	0.00107	CcSEcCtD
Zileuton—Feeling abnormal—Betamethasone—psoriasis	0.000203	0.00107	CcSEcCtD
Zileuton—Feeling abnormal—Dexamethasone—psoriasis	0.000203	0.00107	CcSEcCtD
Zileuton—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000203	0.00921	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—NDUFA5—psoriasis	0.000202	0.00916	CbGpPWpGaD
Zileuton—Vomiting—Mycophenolate mofetil—psoriasis	0.000201	0.00106	CcSEcCtD
Zileuton—Hypersensitivity—Triamcinolone—psoriasis	0.0002	0.00105	CcSEcCtD
Zileuton—Rash—Mycophenolate mofetil—psoriasis	0.0002	0.00105	CcSEcCtD
Zileuton—Dermatitis—Mycophenolate mofetil—psoriasis	0.0002	0.00105	CcSEcCtD
Zileuton—Headache—Mycophenolate mofetil—psoriasis	0.000199	0.00104	CcSEcCtD
Zileuton—Malaise—Methotrexate—psoriasis	0.000198	0.00104	CcSEcCtD
Zileuton—Diarrhoea—Hydrocortisone—psoriasis	0.000198	0.00104	CcSEcCtD
Zileuton—Urticaria—Betamethasone—psoriasis	0.000196	0.00103	CcSEcCtD
Zileuton—Urticaria—Dexamethasone—psoriasis	0.000196	0.00103	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Prednisone—psoriasis	0.000196	0.00103	CcSEcCtD
Zileuton—Dizziness—Prednisolone—psoriasis	0.000195	0.00102	CcSEcCtD
Zileuton—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000195	0.00884	CbGpPWpGaD
Zileuton—Body temperature increased—Dexamethasone—psoriasis	0.000195	0.00102	CcSEcCtD
Zileuton—Body temperature increased—Betamethasone—psoriasis	0.000195	0.00102	CcSEcCtD
Zileuton—Insomnia—Prednisone—psoriasis	0.000194	0.00102	CcSEcCtD
Zileuton—Nausea—Cyclosporine—psoriasis	0.000193	0.00101	CcSEcCtD
Zileuton—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000192	0.00873	CbGpPWpGaD
Zileuton—Pruritus—Triamcinolone—psoriasis	0.000192	0.00101	CcSEcCtD
Zileuton—Dizziness—Hydrocortisone—psoriasis	0.000191	0.001	CcSEcCtD
Zileuton—Dyspepsia—Prednisone—psoriasis	0.000189	0.000991	CcSEcCtD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000188	0.00854	CbGpPWpGaD
Zileuton—Nausea—Mycophenolate mofetil—psoriasis	0.000188	0.000986	CcSEcCtD
Zileuton—Chest pain—Methotrexate—psoriasis	0.000187	0.000981	CcSEcCtD
Zileuton—Arthralgia—Methotrexate—psoriasis	0.000187	0.000981	CcSEcCtD
Zileuton—Myalgia—Methotrexate—psoriasis	0.000187	0.000981	CcSEcCtD
Zileuton—Rash—Prednisolone—psoriasis	0.000186	0.000977	CcSEcCtD
Zileuton—Dermatitis—Prednisolone—psoriasis	0.000186	0.000976	CcSEcCtD
Zileuton—Headache—Prednisolone—psoriasis	0.000185	0.00097	CcSEcCtD
Zileuton—Discomfort—Methotrexate—psoriasis	0.000185	0.00097	CcSEcCtD
Zileuton—Constipation—Prednisone—psoriasis	0.000184	0.000963	CcSEcCtD
Zileuton—Vomiting—Hydrocortisone—psoriasis	0.000184	0.000962	CcSEcCtD
Zileuton—Rash—Hydrocortisone—psoriasis	0.000182	0.000954	CcSEcCtD
Zileuton—Dermatitis—Hydrocortisone—psoriasis	0.000182	0.000953	CcSEcCtD
Zileuton—Headache—Hydrocortisone—psoriasis	0.000181	0.000948	CcSEcCtD
Zileuton—Dizziness—Triamcinolone—psoriasis	0.00018	0.000942	CcSEcCtD
Zileuton—Feeling abnormal—Prednisone—psoriasis	0.000177	0.000928	CcSEcCtD
Zileuton—Nausea—Prednisolone—psoriasis	0.000176	0.00092	CcSEcCtD
Zileuton—Pruritus—Betamethasone—psoriasis	0.000175	0.000914	CcSEcCtD
Zileuton—Pruritus—Dexamethasone—psoriasis	0.000175	0.000914	CcSEcCtD
Zileuton—Vomiting—Triamcinolone—psoriasis	0.000173	0.000906	CcSEcCtD
Zileuton—EPHX2—Metabolism—CYP2S1—psoriasis	0.000172	0.00779	CbGpPWpGaD
Zileuton—Nausea—Hydrocortisone—psoriasis	0.000171	0.000899	CcSEcCtD
Zileuton—Rash—Triamcinolone—psoriasis	0.000171	0.000898	CcSEcCtD
Zileuton—Dermatitis—Triamcinolone—psoriasis	0.000171	0.000897	CcSEcCtD
Zileuton—Urticaria—Prednisone—psoriasis	0.000171	0.000894	CcSEcCtD
Zileuton—Headache—Triamcinolone—psoriasis	0.00017	0.000892	CcSEcCtD
Zileuton—Body temperature increased—Prednisone—psoriasis	0.00017	0.00089	CcSEcCtD
Zileuton—Diarrhoea—Betamethasone—psoriasis	0.000169	0.000884	CcSEcCtD
Zileuton—Diarrhoea—Dexamethasone—psoriasis	0.000169	0.000884	CcSEcCtD
Zileuton—UGT1A9—NRF2 pathway—TGFA—psoriasis	0.000165	0.0075	CbGpPWpGaD
Zileuton—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000164	0.000857	CcSEcCtD
Zileuton—Dizziness—Dexamethasone—psoriasis	0.000163	0.000855	CcSEcCtD
Zileuton—Dizziness—Betamethasone—psoriasis	0.000163	0.000855	CcSEcCtD
Zileuton—Insomnia—Methotrexate—psoriasis	0.000162	0.000851	CcSEcCtD
Zileuton—Nausea—Triamcinolone—psoriasis	0.000161	0.000846	CcSEcCtD
Zileuton—Somnolence—Methotrexate—psoriasis	0.00016	0.000836	CcSEcCtD
Zileuton—ALOX5—Selenium Micronutrient Network—IFNG—psoriasis	0.000159	0.00722	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—HCAR2—psoriasis	0.000159	0.0072	CbGpPWpGaD
Zileuton—Hypersensitivity—Prednisone—psoriasis	0.000158	0.000829	CcSEcCtD
Zileuton—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000158	0.00717	CbGpPWpGaD
Zileuton—Dyspepsia—Methotrexate—psoriasis	0.000158	0.000828	CcSEcCtD
Zileuton—Vomiting—Dexamethasone—psoriasis	0.000157	0.000822	CcSEcCtD
Zileuton—Vomiting—Betamethasone—psoriasis	0.000157	0.000822	CcSEcCtD
Zileuton—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000156	0.00707	CbGpPWpGaD
Zileuton—Rash—Dexamethasone—psoriasis	0.000156	0.000815	CcSEcCtD
Zileuton—Rash—Betamethasone—psoriasis	0.000156	0.000815	CcSEcCtD
Zileuton—Dermatitis—Betamethasone—psoriasis	0.000155	0.000814	CcSEcCtD
Zileuton—Dermatitis—Dexamethasone—psoriasis	0.000155	0.000814	CcSEcCtD
Zileuton—Gastrointestinal disorder—Methotrexate—psoriasis	0.000155	0.000812	CcSEcCtD
Zileuton—Headache—Betamethasone—psoriasis	0.000155	0.00081	CcSEcCtD
Zileuton—Headache—Dexamethasone—psoriasis	0.000155	0.00081	CcSEcCtD
Zileuton—LTB4R—GPCR downstream signaling—CCL20—psoriasis	0.000154	0.00697	CbGpPWpGaD
Zileuton—Pain—Methotrexate—psoriasis	0.000154	0.000804	CcSEcCtD
Zileuton—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000152	0.00691	CbGpPWpGaD
Zileuton—Pruritus—Prednisone—psoriasis	0.000152	0.000796	CcSEcCtD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.00015	0.00678	CbGpPWpGaD
Zileuton—Feeling abnormal—Methotrexate—psoriasis	0.000148	0.000775	CcSEcCtD
Zileuton—Diarrhoea—Prednisone—psoriasis	0.000147	0.00077	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—TNF—psoriasis	0.000147	0.00664	CbGpPWpGaD
Zileuton—Nausea—Dexamethasone—psoriasis	0.000147	0.000768	CcSEcCtD
Zileuton—Nausea—Betamethasone—psoriasis	0.000147	0.000768	CcSEcCtD
Zileuton—Urticaria—Methotrexate—psoriasis	0.000143	0.000747	CcSEcCtD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000142	0.00645	CbGpPWpGaD
Zileuton—Dizziness—Prednisone—psoriasis	0.000142	0.000744	CcSEcCtD
Zileuton—Body temperature increased—Methotrexate—psoriasis	0.000142	0.000744	CcSEcCtD
Zileuton—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.00014	0.00634	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—CCL20—psoriasis	0.00014	0.00633	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TAGAP—psoriasis	0.000138	0.00624	CbGpPWpGaD
Zileuton—Vomiting—Prednisone—psoriasis	0.000137	0.000716	CcSEcCtD
Zileuton—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000136	0.00616	CbGpPWpGaD
Zileuton—Rash—Prednisone—psoriasis	0.000135	0.00071	CcSEcCtD
Zileuton—Dermatitis—Prednisone—psoriasis	0.000135	0.000709	CcSEcCtD
Zileuton—Headache—Prednisone—psoriasis	0.000135	0.000705	CcSEcCtD
Zileuton—ALOX5—Selenium Micronutrient Network—NFKB1—psoriasis	0.000133	0.00601	CbGpPWpGaD
Zileuton—Hypersensitivity—Methotrexate—psoriasis	0.000132	0.000693	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—TP53—psoriasis	0.000129	0.00586	CbGpPWpGaD
Zileuton—Nausea—Prednisone—psoriasis	0.000128	0.000669	CcSEcCtD
Zileuton—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000127	0.00577	CbGpPWpGaD
Zileuton—Pruritus—Methotrexate—psoriasis	0.000127	0.000666	CcSEcCtD
Zileuton—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000126	0.00569	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000124	0.00564	CbGpPWpGaD
Zileuton—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000124	0.00561	CbGpPWpGaD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000123	0.00558	CbGpPWpGaD
Zileuton—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000123	0.00557	CbGpPWpGaD
Zileuton—Diarrhoea—Methotrexate—psoriasis	0.000123	0.000644	CcSEcCtD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000121	0.0055	CbGpPWpGaD
Zileuton—Dizziness—Methotrexate—psoriasis	0.000119	0.000622	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—IL6—psoriasis	0.000118	0.00536	CbGpPWpGaD
Zileuton—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000116	0.00526	CbGpPWpGaD
Zileuton—Vomiting—Methotrexate—psoriasis	0.000114	0.000598	CcSEcCtD
Zileuton—Rash—Methotrexate—psoriasis	0.000113	0.000593	CcSEcCtD
Zileuton—Dermatitis—Methotrexate—psoriasis	0.000113	0.000593	CcSEcCtD
Zileuton—Headache—Methotrexate—psoriasis	0.000112	0.000589	CcSEcCtD
Zileuton—ALOX5—Metabolism—NDUFA5—psoriasis	0.000112	0.00509	CbGpPWpGaD
Zileuton—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000109	0.00493	CbGpPWpGaD
Zileuton—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000107	0.00487	CbGpPWpGaD
Zileuton—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000107	0.00486	CbGpPWpGaD
Zileuton—Nausea—Methotrexate—psoriasis	0.000107	0.000559	CcSEcCtD
Zileuton—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000106	0.00478	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000105	0.00475	CbGpPWpGaD
Zileuton—ALOX5—Selenium Micronutrient Network—TNF—psoriasis	0.000103	0.00467	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	9.88e-05	0.00448	CbGpPWpGaD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	9.65e-05	0.00437	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—CYP2S1—psoriasis	9.55e-05	0.00433	CbGpPWpGaD
Zileuton—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.47e-05	0.00429	CbGpPWpGaD
Zileuton—CYP1A2—Tryptophan metabolism—CAT—psoriasis	9.39e-05	0.00426	CbGpPWpGaD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	9.22e-05	0.00418	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	9.08e-05	0.00412	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9e-05	0.00408	CbGpPWpGaD
Zileuton—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.96e-05	0.00406	CbGpPWpGaD
Zileuton—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	8.64e-05	0.00392	CbGpPWpGaD
Zileuton—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	8.45e-05	0.00383	CbGpPWpGaD
Zileuton—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.4e-05	0.00381	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—CARM1—psoriasis	8.39e-05	0.0038	CbGpPWpGaD
Zileuton—ALOX5—Selenium Micronutrient Network—IL6—psoriasis	8.32e-05	0.00377	CbGpPWpGaD
Zileuton—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.28e-05	0.00376	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—CCL20—psoriasis	8.25e-05	0.00374	CbGpPWpGaD
Zileuton—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.09e-05	0.00367	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.84e-05	0.00355	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—CXCL8—psoriasis	7.35e-05	0.00333	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	7.32e-05	0.00332	CbGpPWpGaD
Zileuton—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.25e-05	0.00328	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	6.91e-05	0.00313	CbGpPWpGaD
Zileuton—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.28e-05	0.00284	CbGpPWpGaD
Zileuton—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.25e-05	0.00283	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—NDUFA5—psoriasis	5.98e-05	0.00271	CbGpPWpGaD
Zileuton—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	5.83e-05	0.00264	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	5.75e-05	0.00261	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.57e-05	0.00253	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.21e-05	0.00236	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—CAT—psoriasis	5.16e-05	0.00234	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—CYP2S1—psoriasis	5.08e-05	0.0023	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.01e-05	0.00227	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—NDUFA5—psoriasis	4.87e-05	0.00221	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—CARM1—psoriasis	4.67e-05	0.00212	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.54e-05	0.00206	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—SOCS1—psoriasis	4.54e-05	0.00206	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.51e-05	0.00204	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	4.47e-05	0.00203	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.36e-05	0.00198	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.34e-05	0.00197	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—TYK2—psoriasis	4.33e-05	0.00196	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—CXCL8—psoriasis	4.15e-05	0.00188	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—CYP2S1—psoriasis	4.14e-05	0.00188	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—APOE—psoriasis	4.01e-05	0.00182	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.94e-05	0.00178	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—CXCL8—psoriasis	3.77e-05	0.00171	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	3.61e-05	0.00164	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PPARG—psoriasis	3.49e-05	0.00158	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.37e-05	0.00153	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.37e-05	0.00153	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—APOE—psoriasis	3.35e-05	0.00152	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—LEP—psoriasis	3.35e-05	0.00152	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—NFKBIA—psoriasis	3.12e-05	0.00142	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—CAT—psoriasis	2.87e-05	0.0013	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.66e-05	0.00121	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—NDUFA5—psoriasis	2.56e-05	0.00116	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TYK2—psoriasis	2.56e-05	0.00116	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—CARM1—psoriasis	2.48e-05	0.00113	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.39e-05	0.00108	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.32e-05	0.00105	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—APOE—psoriasis	2.23e-05	0.00101	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—CXCL8—psoriasis	2.23e-05	0.00101	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—NDUFA5—psoriasis	2.19e-05	0.000992	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—CYP2S1—psoriasis	2.18e-05	0.000987	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.17e-05	0.000984	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—IL6—psoriasis	2.12e-05	0.00096	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—JUN—psoriasis	2.07e-05	0.000939	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.04e-05	0.000925	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—CARM1—psoriasis	2.02e-05	0.000917	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—NFKB1—psoriasis	1.99e-05	0.000904	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PPARG—psoriasis	1.94e-05	0.00088	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.89e-05	0.000857	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—CYP2S1—psoriasis	1.86e-05	0.000844	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—VEGFA—psoriasis	1.81e-05	0.00082	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—STAT3—psoriasis	1.79e-05	0.000812	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—NDUFA5—psoriasis	1.69e-05	0.000766	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—CAT—psoriasis	1.53e-05	0.000692	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—CYP2S1—psoriasis	1.44e-05	0.000651	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TP53—psoriasis	1.37e-05	0.00062	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—IL6—psoriasis	1.25e-05	0.000567	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—CAT—psoriasis	1.24e-05	0.000564	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—APOE—psoriasis	1.19e-05	0.000538	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.14e-05	0.000517	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—CARM1—psoriasis	1.06e-05	0.000482	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PPARG—psoriasis	1.03e-05	0.000468	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.94e-06	0.000451	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.75e-06	0.000442	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—APOE—psoriasis	9.67e-06	0.000438	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—CARM1—psoriasis	9.09e-06	0.000412	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.5e-06	0.000385	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PPARG—psoriasis	8.42e-06	0.000382	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—CARM1—psoriasis	7.01e-06	0.000318	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—CAT—psoriasis	6.54e-06	0.000297	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—CAT—psoriasis	5.59e-06	0.000253	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—APOE—psoriasis	5.08e-06	0.00023	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PPARG—psoriasis	4.43e-06	0.000201	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—APOE—psoriasis	4.34e-06	0.000197	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—CAT—psoriasis	4.31e-06	0.000196	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PPARG—psoriasis	3.78e-06	0.000172	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—APOE—psoriasis	3.35e-06	0.000152	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PPARG—psoriasis	2.92e-06	0.000132	CbGpPWpGaD
